How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Buy
60
ACAD Quote, Financials, Valuation and Earnings
Last price:
$25.13
Seasonality move
:
9.69%
Day range:
$25.06 - $25.77
52-week range:
$13.40 - $28.35
Dividend yield:
0%
P/E ratio:
16.17x
P/S ratio:
4.04x
P/B ratio:
4.64x
Volume:
1.2M
Avg. volume:
1.3M
1-year change:
34.46%
Market cap:
$4.3B
Revenue:
$957.8M
EPS (TTM):
$1.55
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$299.3M | $0.20 | 13.72% | 13.07% | $31.05 |
|
ANIP
ANI Pharmaceuticals, Inc.
|
$235.7M | $1.99 | 5.9% | 130.85% | $110.38 |
|
CPRX
Catalyst Pharmaceuticals, Inc.
|
$149M | $0.63 | 1.73% | 35.24% | $34.57 |
|
FOLD
Amicus Therapeutics, Inc.
|
$182.1M | $0.15 | 29.62% | 234.42% | $14.50 |
|
PBYI
Puma Biotechnology, Inc.
|
$55M | $0.12 | 16.12% | -41.13% | $5.00 |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$3.8B | $10.83 | 19.66% | 41.09% | $846.85 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$25.13 | $31.05 | $4.3B | 16.17x | $0.00 | 0% | 4.04x |
|
ANIP
ANI Pharmaceuticals, Inc.
|
$81.85 | $110.38 | $1.8B | 50.20x | $0.00 | 0% | 2.00x |
|
CPRX
Catalyst Pharmaceuticals, Inc.
|
$24.30 | $34.57 | $3B | 14.18x | $0.00 | 0% | 5.34x |
|
FOLD
Amicus Therapeutics, Inc.
|
$14.29 | $14.50 | $4.4B | -- | $0.00 | 0% | 7.31x |
|
PBYI
Puma Biotechnology, Inc.
|
$6.48 | $5.00 | $326.5M | 8.75x | $0.00 | 0% | 1.53x |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$741.45 | $846.85 | $77.9B | 17.84x | $0.88 | 0.48% | 5.62x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.825 | 1.52% | 2.70x |
|
ANIP
ANI Pharmaceuticals, Inc.
|
55.53% | -0.736 | 30.7% | 2.40x |
|
CPRX
Catalyst Pharmaceuticals, Inc.
|
0.31% | -0.785 | 0.12% | 6.19x |
|
FOLD
Amicus Therapeutics, Inc.
|
65.77% | -0.323 | 18.22% | 1.91x |
|
PBYI
Puma Biotechnology, Inc.
|
26.26% | 0.733 | 15.34% | 1.57x |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
7.97% | -0.094 | 3.34% | 4.22x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
ANIP
ANI Pharmaceuticals, Inc.
|
$111.8M | $22.8M | 3.31% | 8.22% | 10.02% | $37.9M |
|
CPRX
Catalyst Pharmaceuticals, Inc.
|
$116.4M | $66.3M | 27.37% | 27.48% | 44.66% | $32.4M |
|
FOLD
Amicus Therapeutics, Inc.
|
$147.7M | $34.3M | -2.18% | -7.02% | 20.27% | $35.3M |
|
PBYI
Puma Biotechnology, Inc.
|
$42.3M | $9.6M | 23.32% | 38.49% | 17.57% | $9.7M |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$3.3B | $898.6M | 13.68% | 14.93% | 23.13% | $1.4B |
ACADIA Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns ACAD or ANIP?
ANI Pharmaceuticals, Inc. has a net margin of 25.76% compared to ACADIA Pharmaceuticals, Inc.'s net margin of 10.59%. ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23% beat ANI Pharmaceuticals, Inc.'s return on equity of 8.22%.
Company Gross Margin Earnings Per Share Invested Capital ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M ANIPANI Pharmaceuticals, Inc.49.07% $1.13 $1.1B -
What do Analysts Say About ACAD or ANIP?
ACADIA Pharmaceuticals, Inc. has a consensus price target of $31.05, signalling upside risk potential of 23.57%. On the other hand ANI Pharmaceuticals, Inc. has an analysts' consensus of $110.38 which suggests that it could grow by 34.85%. Given that ANI Pharmaceuticals, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe ANI Pharmaceuticals, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ACADACADIA Pharmaceuticals, Inc.9 6 1 ANIPANI Pharmaceuticals, Inc.4 1 0 -
Is ACAD or ANIP More Risky?
ACADIA Pharmaceuticals, Inc. has a beta of 0.679, which suggesting that the stock is 32.083% less volatile than S&P 500. In comparison ANI Pharmaceuticals, Inc. has a beta of 0.505, suggesting its less volatile than the S&P 500 by 49.46%.
-
Which is a Better Dividend Stock ACAD or ANIP?
ACADIA Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ANI Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ACADIA Pharmaceuticals, Inc. pays -- of its earnings as a dividend. ANI Pharmaceuticals, Inc. pays out 8.77% of its earnings as a dividend. ANI Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ACAD or ANIP?
ACADIA Pharmaceuticals, Inc. quarterly revenues are $278.6M, which are larger than ANI Pharmaceuticals, Inc. quarterly revenues of $227.8M. ACADIA Pharmaceuticals, Inc.'s net income of $71.8M is higher than ANI Pharmaceuticals, Inc.'s net income of $24.1M. Notably, ACADIA Pharmaceuticals, Inc.'s price-to-earnings ratio is 16.17x while ANI Pharmaceuticals, Inc.'s PE ratio is 50.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ACADIA Pharmaceuticals, Inc. is 4.04x versus 2.00x for ANI Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACADACADIA Pharmaceuticals, Inc.4.04x 16.17x $278.6M $71.8M ANIPANI Pharmaceuticals, Inc.2.00x 50.20x $227.8M $24.1M
-
Which has Higher Returns ACAD or CPRX?
Catalyst Pharmaceuticals, Inc. has a net margin of 25.76% compared to ACADIA Pharmaceuticals, Inc.'s net margin of 35.57%. ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23% beat Catalyst Pharmaceuticals, Inc.'s return on equity of 27.48%.
Company Gross Margin Earnings Per Share Invested Capital ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M CPRXCatalyst Pharmaceuticals, Inc.78.44% $0.42 $923.1M -
What do Analysts Say About ACAD or CPRX?
ACADIA Pharmaceuticals, Inc. has a consensus price target of $31.05, signalling upside risk potential of 23.57%. On the other hand Catalyst Pharmaceuticals, Inc. has an analysts' consensus of $34.57 which suggests that it could grow by 42.27%. Given that Catalyst Pharmaceuticals, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Catalyst Pharmaceuticals, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ACADACADIA Pharmaceuticals, Inc.9 6 1 CPRXCatalyst Pharmaceuticals, Inc.7 0 0 -
Is ACAD or CPRX More Risky?
ACADIA Pharmaceuticals, Inc. has a beta of 0.679, which suggesting that the stock is 32.083% less volatile than S&P 500. In comparison Catalyst Pharmaceuticals, Inc. has a beta of 0.722, suggesting its less volatile than the S&P 500 by 27.786%.
-
Which is a Better Dividend Stock ACAD or CPRX?
ACADIA Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ACADIA Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Catalyst Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ACAD or CPRX?
ACADIA Pharmaceuticals, Inc. quarterly revenues are $278.6M, which are larger than Catalyst Pharmaceuticals, Inc. quarterly revenues of $148.4M. ACADIA Pharmaceuticals, Inc.'s net income of $71.8M is higher than Catalyst Pharmaceuticals, Inc.'s net income of $52.8M. Notably, ACADIA Pharmaceuticals, Inc.'s price-to-earnings ratio is 16.17x while Catalyst Pharmaceuticals, Inc.'s PE ratio is 14.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ACADIA Pharmaceuticals, Inc. is 4.04x versus 5.34x for Catalyst Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACADACADIA Pharmaceuticals, Inc.4.04x 16.17x $278.6M $71.8M CPRXCatalyst Pharmaceuticals, Inc.5.34x 14.18x $148.4M $52.8M
-
Which has Higher Returns ACAD or FOLD?
Amicus Therapeutics, Inc. has a net margin of 25.76% compared to ACADIA Pharmaceuticals, Inc.'s net margin of 10.24%. ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.
Company Gross Margin Earnings Per Share Invested Capital ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M -
What do Analysts Say About ACAD or FOLD?
ACADIA Pharmaceuticals, Inc. has a consensus price target of $31.05, signalling upside risk potential of 23.57%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.50 which suggests that it could grow by 1.47%. Given that ACADIA Pharmaceuticals, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe ACADIA Pharmaceuticals, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ACADACADIA Pharmaceuticals, Inc.9 6 1 FOLDAmicus Therapeutics, Inc.0 7 0 -
Is ACAD or FOLD More Risky?
ACADIA Pharmaceuticals, Inc. has a beta of 0.679, which suggesting that the stock is 32.083% less volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.417, suggesting its less volatile than the S&P 500 by 58.311%.
-
Which is a Better Dividend Stock ACAD or FOLD?
ACADIA Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ACADIA Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ACAD or FOLD?
ACADIA Pharmaceuticals, Inc. quarterly revenues are $278.6M, which are larger than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. ACADIA Pharmaceuticals, Inc.'s net income of $71.8M is higher than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, ACADIA Pharmaceuticals, Inc.'s price-to-earnings ratio is 16.17x while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ACADIA Pharmaceuticals, Inc. is 4.04x versus 7.31x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACADACADIA Pharmaceuticals, Inc.4.04x 16.17x $278.6M $71.8M FOLDAmicus Therapeutics, Inc.7.31x -- $169.1M $17.3M
-
Which has Higher Returns ACAD or PBYI?
Puma Biotechnology, Inc. has a net margin of 25.76% compared to ACADIA Pharmaceuticals, Inc.'s net margin of 16.24%. ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23% beat Puma Biotechnology, Inc.'s return on equity of 38.49%.
Company Gross Margin Earnings Per Share Invested Capital ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M PBYIPuma Biotechnology, Inc.77.65% $0.17 $156.3M -
What do Analysts Say About ACAD or PBYI?
ACADIA Pharmaceuticals, Inc. has a consensus price target of $31.05, signalling upside risk potential of 23.57%. On the other hand Puma Biotechnology, Inc. has an analysts' consensus of $5.00 which suggests that it could fall by -22.84%. Given that ACADIA Pharmaceuticals, Inc. has higher upside potential than Puma Biotechnology, Inc., analysts believe ACADIA Pharmaceuticals, Inc. is more attractive than Puma Biotechnology, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ACADACADIA Pharmaceuticals, Inc.9 6 1 PBYIPuma Biotechnology, Inc.0 1 0 -
Is ACAD or PBYI More Risky?
ACADIA Pharmaceuticals, Inc. has a beta of 0.679, which suggesting that the stock is 32.083% less volatile than S&P 500. In comparison Puma Biotechnology, Inc. has a beta of 1.187, suggesting its more volatile than the S&P 500 by 18.747%.
-
Which is a Better Dividend Stock ACAD or PBYI?
ACADIA Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Puma Biotechnology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ACADIA Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Puma Biotechnology, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ACAD or PBYI?
ACADIA Pharmaceuticals, Inc. quarterly revenues are $278.6M, which are larger than Puma Biotechnology, Inc. quarterly revenues of $54.5M. ACADIA Pharmaceuticals, Inc.'s net income of $71.8M is higher than Puma Biotechnology, Inc.'s net income of $8.8M. Notably, ACADIA Pharmaceuticals, Inc.'s price-to-earnings ratio is 16.17x while Puma Biotechnology, Inc.'s PE ratio is 8.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ACADIA Pharmaceuticals, Inc. is 4.04x versus 1.53x for Puma Biotechnology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACADACADIA Pharmaceuticals, Inc.4.04x 16.17x $278.6M $71.8M PBYIPuma Biotechnology, Inc.1.53x 8.75x $54.5M $8.8M
-
Which has Higher Returns ACAD or REGN?
Regeneron Pharmaceuticals, Inc. has a net margin of 25.76% compared to ACADIA Pharmaceuticals, Inc.'s net margin of 21.74%. ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93%.
Company Gross Margin Earnings Per Share Invested Capital ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M REGNRegeneron Pharmaceuticals, Inc.85.9% $7.86 $34B -
What do Analysts Say About ACAD or REGN?
ACADIA Pharmaceuticals, Inc. has a consensus price target of $31.05, signalling upside risk potential of 23.57%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $846.85 which suggests that it could grow by 12.75%. Given that ACADIA Pharmaceuticals, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe ACADIA Pharmaceuticals, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ACADACADIA Pharmaceuticals, Inc.9 6 1 REGNRegeneron Pharmaceuticals, Inc.17 8 0 -
Is ACAD or REGN More Risky?
ACADIA Pharmaceuticals, Inc. has a beta of 0.679, which suggesting that the stock is 32.083% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.390, suggesting its less volatile than the S&P 500 by 60.965%.
-
Which is a Better Dividend Stock ACAD or REGN?
ACADIA Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.48% to investors and pays a quarterly dividend of $0.88 per share. ACADIA Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out 8.49% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ACAD or REGN?
ACADIA Pharmaceuticals, Inc. quarterly revenues are $278.6M, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.9B. ACADIA Pharmaceuticals, Inc.'s net income of $71.8M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $844.6M. Notably, ACADIA Pharmaceuticals, Inc.'s price-to-earnings ratio is 16.17x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 17.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ACADIA Pharmaceuticals, Inc. is 4.04x versus 5.62x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACADACADIA Pharmaceuticals, Inc.4.04x 16.17x $278.6M $71.8M REGNRegeneron Pharmaceuticals, Inc.5.62x 17.84x $3.9B $844.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
50
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Sell
40
GDXU alert for Jan 31
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 38.85% over the past day.
Sell
34
PFSI alert for Jan 31
PennyMac Financial Services, Inc. [PFSI] is down 33.21% over the past day.
Sell
40
SHNY alert for Jan 31
MicroSectors Gold 3X Leveraged ETN [SHNY] is down 31.56% over the past day.
